The Role of Biomarker Testing in Melanoma

EP: 1.An Overview of the Landscape Surrounding Melanoma

Now Viewing

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® discussion involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment focuses on the role of biomarker testing and mutational status impact in patients with newly diagnosed melanoma.

Dr Khushalani emphasizes determining mutational status early on in the appropriate clinical context. For example, testing is not done routinely for early-stage disease, but should be done for stage III and definitely stage IV metastatic disease. Testing should include tumor mutational profiling and BRAF testing, as BRAF mutations occur in about 45% of melanomas. Additional molecular profiling or next-generation sequencing can identify other less common mutations like NRAS (second most common) and NF1 (third most common). Tumors lacking these mutations are termed “wild type.”

It is important to test for BRAF because there are MAP kinase pathway inhibitors targeting BRAF V600 mutations that are approved for metastatic melanoma and as adjuvant therapy for high-risk resected stage III disease.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.